Area of research
Statistics, Probability and Uncertainty · Endocrinology, Diabetes and Metabolism
Research interest
Research focused on Vemurafenib and Bevacizumab, with related work in Salmonella enterica, Placebo, Meta-analysis. Notable publications include 'Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer', 'Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial', and 'Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials'.
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer
Salmonella enterica Serovar Typhimurium Interacts with CD209 Receptors To Promote Host Dissemination and Infection
Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Mobile phone text messages for improving adherence to antiretroviral therapy (ART): an individual patient data meta-analysis of randomised trials
The impact of a cardiovascular health awareness program (CHAP) on reducing blood pressure: a prospective cohort study